科伦博泰生物-B（股票代码：06990）宣布，其创新药物萨坦珠单抗（Sacituzumab Tirumotecan，简称Sac-TMT）已获得国家药品监督管理局（NMPA）批准，用于治疗HR阳性、HER2阴性（HR+/HER2-）乳腺癌患者。这是该药物在中国获批的第四项适应症，标志着其在肿瘤治疗领域的应用进一步扩展。
此次获批基于临床试验数据，显示萨坦珠单抗在HR+/HER2-乳腺癌患者中表现出显著的疗效和可控的安全性。该药物作为一种抗体偶联药物（ADC），通过靶向特定抗原递送细胞毒性药物，精准攻击肿瘤细胞，为患者提供了新的治疗选择。
科伦博泰生物-B持续致力于创新药物的研发与商业化，此次新适应症的获批将有望提升萨坦珠单抗的市场潜力，并为公司未来业绩增长注入动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.